Iberdomide

Iberdomide
Identifiers
	IUPAC name (3S)-3-[7-[[4-(Morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione;
CAS Number	1323403-33-3;
PubChem CID	67335295;
IUPHAR/BPS	9618;
DrugBank	DB12101;
ChemSpider	52085251;
UNII	8V66F27X44;
KEGG	D11134;
ChEMBL	ChEMBL3989927;
Chemical and physical data
Formula	C25H27N3O5
Molar mass	449.507 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC(=O)NC(=O)[C@H]1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5;
	InChI InChI=1S/C25H27N3O5/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27/h1-7,21H,8-16H2,(H,26,29,30)/t21-/m0/s1; Key:IXZOHGPZAQLIBH-NRFANRHFSA-N;

Iberdomide is an experimental thalidomide analog that works as an cereblon E3 ligase modulator; it has a higher binding affinity than lenalidomide or pomalidomide. It is developed by Bristol Myers Squibb for various cancers and was also tested in people with lupus.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.